Correspondence » Legacy Notes » (Blank)

07/10/2014 · Document 143 of 162 · Page 216 of

M 1 @ < 0

1119





BOYAL FREE HOSPITAL POHO STREET LONGON WWY 200

TELEPHONE CITE 704 GLOD



THE HAEMOPHILIA CENTRE & HAEMOSTASIS UNIT

Telephone: 0171-830 2068 Fax No.: 0171-830 2178

Mr GRO-B GRO-B London GRO-B

3rd December 1997

Dear Mr GRO-B

It is our practice to keep you informed of issues that relate to haemophilia care. You may have heard or read about CJD and the concerns that the agent causing this may be transmitted by blood transfusion and blood products. At the present time there is no evidence for this. The basis for scientific speculation is that the new form of CJD (new variant CJD) infects the lymphocytes, a type of white cells which are found in the blood. Blood products used for the treatment of inherited bleeding disorders do not contain white cells.

As a consequence of these concerns, and as a precautionary measure, there have been two recent recalls of BPL Factor VIII batches because it was found that "a donor had not met the current health requirements for CJD".

According to our records, you have never been treated with these batches.

What is known about the transmission of the new variant CJD to humans is that it has probably arisen from ingestion of beef products containing the agent responsible for BSE in cattle. The medical and scientific issues are complex. We will ensure that we keep them under close review, as new information becomes available, so that we may keep you fully informed. In the meantime, if you have any concerns you wish to discuss, in the first instance please contact one of the nurses at the Centre on 0171 830 2557.

Yours sincerely,

Professor Christine Lee Director Dr John Pasi Consultant Dr David Perry Senior Lecturer

GRO-B

		The state of the s					
_oose Fili					/6	F	٠,
	прх		ALVIV	MALES	33 1 8 %	Lank	ı

09/12/2014 · Document 10 of 12 · Page 73 of 516



111101






CONFIDENTIAL PATIENT VCJD EXPOSURE ASSESSMENT FORM

1. To be completed for all patients with bleeding disorders $\mbox{\rm ``lincluding congenital antithrombin III deficiency),}$

2. Por each patient please complete all parts of the form, print and place copy in patient's medical notes.

3. A copy should also be sent in confidence to the UKHCDO National Haemophilla Database Coordinator, University Department of Haematology, Manchester Royal Infirmary, M13 9WL



PART 1: PATIENT INFORMATION

UKHCOO Number: GRO-B DATE of BIRTH

NAME of Haemophilia Centre: NOYAL FLOE

NUMBER of Haemophilla Centre: 086

Did the patient receive ANY UK sourced pooled factor concentrates or antithrombin* between 1980 and 2001?* Factor VII, factor IX, factor VII, factor XI and factor XIII, prothrombin complex concentrates and antithrombin



PATIENT IS "AT-RISK" OF VOID FOR PUBLIC HEALTH PURPOSES PATIENT IS NOT "AT-RISK" OF VOID FOR PUBLIC HEALTH PURPOSES

PART 2: EXPOSURE ASSESSMENT

Please complete the dates of first and last dose, and the total dose received for the batches listed below. Where no product was received please record 0 for the total dose. This information is important for public health monitoring, to inform public health precautions and future policy for patients with bleeding disorders.

BRAND NAME	VIAL SIZE (IU)	BATCH NUMBER	DATE of RELEASE	DATE of FIRST DOSE	DATE of LAST DOSE	TOTAL DOS
Factor VIII			***************************************	.1	L	L
87	500	FHB4116	26.06.92			0
BY	500	FHB4189	14.04.93			b
87	500	FH84419*	31.07.95			D
BY	500	FH84547*	01.11.96			b
57	500	FH84596*	06.05.97			0
87	250	rHC0289	23.05.90			ь
87	250	PHC0369	18.12.90			0
ay	250	FHC4237	09.03.94			0
REPLENATE	500	FHE4437	21.09.95	19/8/96	19/8/96	485
REPLENATE	500	FHE4536*	04,09,96			D
REPLENATE	500	FHE4548*	17.10.96			0
REPLENATE	1000	FHF4625	29,07,97	19/9/92	19/9/92	1936
High purity F8	500	FHM3990	17.11.91			D
High purity F8	500	FHM4054	06.05.92			0
Z6	160	0301-70320	02.08.87			0
28	190	0304-70510	14,07,87			O

batches previously notified by Bio Products Laboratory (8PL) to consignees.

IONSIGNEES VCIO and Plantia Products - Pallent vCIO Exposure Allessament Form vention H1.0 7th September 2004 Page L of 2

Loose Filing » Legacy Notes » (Blank)

09/12/2014 · Document 10 of 12 · Page 75 of 516

1 1 0 4 1



.

PATIENT VCJD EXPOSURE ASSESSMENT FORM (cont)

BRAND NAME	VIAL SIZE (IU)	BATCH NUMBER	DATE of RELEASE	DATE of FIRST DOSE	DATE of LAST DOSE	TOTAL DOSE (IU)
Factor IX						
9A	600	F)A0092	24.05.90			0
9A	600	F)442398	09.07.93			0
9.4	600	F3A4308	18.06.94			0
REPLENINE	500	FJM4327	10.10.94			0
REPLEMINE	500	F3M4437	27.11.95			0
REPLENINE	500	FJM4596*	23.04.97			0
REPLENINE	500	F)M4625	07.07.97			0
HT DEFIX	276	3502-70210	14.09.87			D
dthrombin						
ANTITHROMBIN	500	ATA4535*	20.12.96			O

^{*} batches previously notified by Bio Products Laboratory (BPL) to consignees

for batches of factor VIII, factor IX and antithrombin listed above

Has the patient asked to know if they received the implicated batch(s)?

YES / NO

When was the patient informed if they received the implicated batch(s)?

DATE

NAME of ASSESSOR-	D. C. MILLAR SIGNATURE:	GRO-C
DATE: 22/9/		Ugm

sCID and Plasme Products - Patient vCID Exposure Assessment Form version (1),0 7th September 2004 Page 2 of 2